Ann: 2021 AGM Chairman's Address and CEO Presentation, page-22

i got the impression that the focus was on a license deal to use the platform, or indeed, even use our drugs. This could not happen until NHP data was released, so now it can. If the US want a big market, diabetic blindness is the obvious go to and that is one of our drugs in development. Let’s see if that is where we end up. Ie , a cash injection upfront and funds to to take that thru the clinic over the next 4 years. That would see some sp action for sure. Meanwhile if that does not happen we just continue with our 3 niche
drugs and eventually get traction that way.
We could also just provide the delivery system to say Sarepta as we can probably solve some of their issues, and we know they are watching on…..

drug works….tick
platform works…..tick.
validation by market…..? One day.